|
Gene: TH |
Gene summary for TH |
Gene summary. |
Gene information | Species | Human | Gene symbol | TH | Gene ID | 7054 |
Gene name | tyrosine hydroxylase | |
Gene Alias | DYT14 | |
Cytomap | 11p15.5 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P07101 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7054 | TH | C04 | Human | Oral cavity | OSCC | 2.26e-15 | 7.94e-01 | 0.2633 |
7054 | TH | C21 | Human | Oral cavity | OSCC | 3.65e-07 | 1.94e-01 | 0.2678 |
7054 | TH | C30 | Human | Oral cavity | OSCC | 2.87e-17 | 6.63e-01 | 0.3055 |
7054 | TH | C51 | Human | Oral cavity | OSCC | 4.98e-04 | 2.56e-01 | 0.2674 |
7054 | TH | SYSMH5 | Human | Oral cavity | OSCC | 3.73e-03 | 1.34e-01 | 0.0647 |
7054 | TH | P4_cSCC | Human | Skin | cSCC | 3.76e-02 | 9.18e-02 | -0.00290000000000005 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0050658110 | Thyroid | PTC | RNA transport | 98/5968 | 163/18723 | 9.08e-14 | 4.90e-12 | 98 |
GO:2001234113 | Thyroid | PTC | negative regulation of apoptotic signaling pathway | 124/5968 | 224/18723 | 2.57e-13 | 1.32e-11 | 124 |
GO:0001933113 | Thyroid | PTC | negative regulation of protein phosphorylation | 173/5968 | 342/18723 | 3.46e-13 | 1.75e-11 | 173 |
GO:1903313110 | Thyroid | PTC | positive regulation of mRNA metabolic process | 76/5968 | 118/18723 | 3.60e-13 | 1.80e-11 | 76 |
GO:0044403113 | Thyroid | PTC | biological process involved in symbiotic interaction | 151/5968 | 290/18723 | 5.83e-13 | 2.85e-11 | 151 |
GO:0045727113 | Thyroid | PTC | positive regulation of translation | 84/5968 | 136/18723 | 6.52e-13 | 3.08e-11 | 84 |
GO:0042326113 | Thyroid | PTC | negative regulation of phosphorylation | 189/5968 | 385/18723 | 1.00e-12 | 4.64e-11 | 189 |
GO:0150115112 | Thyroid | PTC | cell-substrate junction organization | 67/5968 | 101/18723 | 1.14e-12 | 5.23e-11 | 67 |
GO:000635416 | Thyroid | PTC | DNA-templated transcription, elongation | 62/5968 | 91/18723 | 1.30e-12 | 5.91e-11 | 62 |
GO:0051099113 | Thyroid | PTC | positive regulation of binding | 100/5968 | 173/18723 | 1.56e-12 | 6.96e-11 | 100 |
GO:1901361111 | Thyroid | PTC | organic cyclic compound catabolic process | 231/5968 | 495/18723 | 2.55e-12 | 1.12e-10 | 231 |
GO:0015931110 | Thyroid | PTC | nucleobase-containing compound transport | 120/5968 | 222/18723 | 5.45e-12 | 2.35e-10 | 120 |
GO:0006446110 | Thyroid | PTC | regulation of translational initiation | 55/5968 | 79/18723 | 6.21e-12 | 2.63e-10 | 55 |
GO:0043487111 | Thyroid | PTC | regulation of RNA stability | 97/5968 | 170/18723 | 9.51e-12 | 3.97e-10 | 97 |
GO:0030111110 | Thyroid | PTC | regulation of Wnt signaling pathway | 163/5968 | 328/18723 | 1.05e-11 | 4.29e-10 | 163 |
GO:000704420 | Thyroid | PTC | cell-substrate junction assembly | 62/5968 | 95/18723 | 2.28e-11 | 8.76e-10 | 62 |
GO:0097191113 | Thyroid | PTC | extrinsic apoptotic signaling pathway | 117/5968 | 219/18723 | 2.73e-11 | 1.03e-09 | 117 |
GO:005102817 | Thyroid | PTC | mRNA transport | 78/5968 | 130/18723 | 3.44e-11 | 1.26e-09 | 78 |
GO:0061013111 | Thyroid | PTC | regulation of mRNA catabolic process | 94/5968 | 166/18723 | 3.55e-11 | 1.29e-09 | 94 |
GO:0051348113 | Thyroid | PTC | negative regulation of transferase activity | 137/5968 | 268/18723 | 3.78e-11 | 1.36e-09 | 137 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501230 | Oral cavity | OSCC | Parkinson disease | 188/3704 | 266/8465 | 1.82e-19 | 1.52e-17 | 7.75e-18 | 188 |
hsa05012113 | Oral cavity | OSCC | Parkinson disease | 188/3704 | 266/8465 | 1.82e-19 | 1.52e-17 | 7.75e-18 | 188 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TH | SNV | Missense_Mutation | c.58N>C | p.Glu20Gln | p.E20Q | P07101 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.998) | TCGA-E2-A1LS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cyclophosphamide | SD | |
TH | SNV | Missense_Mutation | novel | c.307N>A | p.Ala103Thr | p.A103T | P07101 | protein_coding | tolerated(0.31) | benign(0.055) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TH | SNV | Missense_Mutation | rs760640869 | c.374N>T | p.Ser125Leu | p.S125L | P07101 | protein_coding | deleterious(0.01) | benign(0.058) | TCGA-EA-A3QD-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
TH | SNV | Missense_Mutation | c.235N>A | p.Glu79Lys | p.E79K | P07101 | protein_coding | deleterious(0.04) | probably_damaging(0.957) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
TH | SNV | Missense_Mutation | rs372409517 | c.677N>T | p.Ser226Leu | p.S226L | P07101 | protein_coding | deleterious(0.01) | possibly_damaging(0.661) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TH | SNV | Missense_Mutation | novel | c.1201N>C | p.Tyr401His | p.Y401H | P07101 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TH | SNV | Missense_Mutation | novel | c.944N>A | p.Gly315Asp | p.G315D | P07101 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
TH | SNV | Missense_Mutation | rs757607038 | c.806C>T | p.Thr269Met | p.T269M | P07101 | protein_coding | deleterious(0.04) | possibly_damaging(0.904) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TH | SNV | Missense_Mutation | c.721N>A | p.Ala241Thr | p.A241T | P07101 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-F4-6703-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
TH | SNV | Missense_Mutation | rs200751977 | c.1492G>A | p.Asp498Asn | p.D498N | P07101 | protein_coding | deleterious(0.02) | benign(0.077) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7054 | TH | ENZYME, DRUGGABLE GENOME | L-Phenylalanine | PHENYLALANINE | ||
7054 | TH | ENZYME, DRUGGABLE GENOME | methylphenidate | METHYLPHENIDATE | 26810137 | |
7054 | TH | ENZYME, DRUGGABLE GENOME | metyrosine | METYROSINE | ||
7054 | TH | ENZYME, DRUGGABLE GENOME | EPO | EPOETIN ALFA | 16368081 | |
7054 | TH | ENZYME, DRUGGABLE GENOME | TETRAHYDROBIOPTERIN | SAPROPTERIN | ||
7054 | TH | ENZYME, DRUGGABLE GENOME | SERTRALINE HYDROCHLORIDE | 8629887 | ||
7054 | TH | ENZYME, DRUGGABLE GENOME | DEHYDROEPIANDROSTERONE | PRASTERONE | 8704732 | |
7054 | TH | ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL1200862 | METYROSINE | |
7054 | TH | ENZYME, DRUGGABLE GENOME | IFN | 8724983 | ||
7054 | TH | ENZYME, DRUGGABLE GENOME | DOXYCYCLINE | DOXYCYCLINE | 15585109 |
Page: 1 2 3 4 |